Cargando…

Structural basis of DUX4/IGH-driven transactivation

Oncogenic fusions are major drivers in leukemogenesis and may serve as potent targets for treatment. DUX4/IGHs have been shown to trigger the abnormal expression of ERG(alt) through binding to DUX4-Responsive-Element (DRE), which leads to B-cell differentiation arrest and a full-fledged B-ALL. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xue, Zhang, Weina, Wu, Haiyan, Huang, Jinyan, Zhang, Ming, Wang, Pengran, Zhang, Hao, Chen, Zhu, Chen, Sai-Juan, Meng, Guoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990521/
https://www.ncbi.nlm.nih.gov/pubmed/29572508
http://dx.doi.org/10.1038/s41375-018-0093-1
Descripción
Sumario:Oncogenic fusions are major drivers in leukemogenesis and may serve as potent targets for treatment. DUX4/IGHs have been shown to trigger the abnormal expression of ERG(alt) through binding to DUX4-Responsive-Element (DRE), which leads to B-cell differentiation arrest and a full-fledged B-ALL. Here, we determined the crystal structures of Apo- and DNA(DRE)-bound DUX4(HD2) and revealed a clamp-like transactivation mechanism via the double homeobox domain. Biophysical characterization showed that mutations in the interacting interfaces significantly impaired the DNA binding affinity of DUX4 homeobox. These mutations, when introduced into DUX4/IGH, abrogated its transactivation activity in Reh cells. More importantly, the structure-based mutants significantly impaired the inhibitory effects of DUX4/IGH upon B-cell differentiation in mouse progenitor cells. All these results help to define a key DUX4/IGH-DRE recognition/step in B-ALL.